Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
C-Rad AB Class B ( ($SE:CRAD.B) ) has shared an update.
C-RAD reported a weaker fourth quarter and full-year 2025, with order intake and revenue declining in the quarter and EBIT margin contracting, although gross margins remained strong and full-year order intake rose slightly. Earnings and earnings per share fell sharply year-on-year, but adjusted figures excluding one-time management change costs and negative currency effects showed more resilient profitability, and the board proposed a modest dividend of SEK 0.10 per share.
New CEO Tomas Blomquist emphasized that C-RAD has solid fundamentals—technology, balance sheet and market position—but needs sharper focus and execution to unlock its full potential. He outlined priorities for 2026 centered on commercial execution, clearer accountability, streamlined structures and a focused innovation pipeline, aiming to reduce business volatility, strengthen profitability and build C-RAD into a more predictable, globally scalable cancer care solutions provider.
The most recent analyst rating on ($SE:CRAD.B) stock is a Hold with a SEK35.00 price target. To see the full list of analyst forecasts on C-Rad AB Class B stock, see the SE:CRAD.B Stock Forecast page.
More about C-Rad AB Class B
C-RAD AB is a Swedish medical technology company specializing in advanced positioning and scanning solutions for radiotherapy in cancer care. Its products and services aim to enhance precision, efficiency and workflow in radiation treatment, and the company operates globally in a structurally growing market for high-quality radiotherapy solutions.
Average Trading Volume: 41,575
Technical Sentiment Signal: Sell
Current Market Cap: SEK1.08B
For a thorough assessment of CRAD.B stock, go to TipRanks’ Stock Analysis page.